Letybo
LetibotulinumtoxinA | Latest Korean botulinum toxin, FDA-approved 2024
About This Treatment
Letybo (Hugel, South Korea) is LetibotulinumtoxinA newly FDA-approved for cosmetic use in 2024. Developed by Korean biotech company Hugel. Multiple trials suggest efficacy equivalent to or exceeding Botox Cosmetic.
Established safety/efficacy with ~3 years South Korean market experience. Faster onset (some report mild effects 1-2 days post-injection). High patient satisfaction. Expected to expand globally.
Mechanism of Action
LetibotulinumtoxinA is a subtype of BoNT-A that cleaves SNAP-25 similarly. Subtle amino acid sequence differences may alter cell penetration speed or nerve terminal binding affinity. Clinically shows slightly faster onset, though detailed mechanism not fully elucidated.
Indications
Expected Results
Fast onset—some patients report mild effects at 1-2 days. Peak at 2-4 weeks. Duration 3-4 months equivalent to Botox. Korean clinical data show very high patient satisfaction.
Clinical Evidence
Risks & Side Effects
Injection pain/swelling/bruising. Brow ptosis and dry eye risk presumed equivalent to Botox Cosmetic. Limited large-scale long-term data on antibody formation (newly approved 2024). Conservative dosing recommended for first treatment.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition